ClinicalTrials.gg
RecruitingNCT05067764REMEDYUpdated Apr 23, 2026

Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease

An interventional study of Aponeurectomy with grafting and Aponeurectomy alone in Dupuytren's Disease, sponsored by Elsan. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Elsan · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence.

Various medical and surgical treatments are available.

Read the detailed description

Among these treatments, none to date can eliminate recurrences, which are still too frequent.

Open aponeurectomy (consisting of surgical curettage of the fibrotic cords) remains for the moment the reference technique for treating Dupuytren's disease, with recurrences (between 12 and 39%), but less frequent than the needle technique (50 to 85%).

Could the addition of adipose tissue in the resection areas of Dupytren's fibrosis reduce the rate of recurrence (by the inhibitory action of ADCs on myofibroblasts) in addition to reconstructing the hypodermis in the cavity left by the resection of the cords and improving the quality of the scars? The investigators insist on the fact that this is a homotopic and homologous adipose tissue graft, in closed circuit without denaturation or adjuvant products.

Since, to our knowledge, no other team has used "lipofilling" as an adjuvant treatment to the open resection technique of Dupuytren's cords (aponeurectomy), the investigators first conducted a clinical feasibility and safety study on 70 patients between 2012 and 2017 (currently being published by Springer Editions).

The investigators now wish to conduct a prospective comparative study between patients operated by aponeurectomy WITH (experimental group) and WITHOUT (control group) addition of autologous adipose tissue in the resection areas of Dupuytren's cords.

02

Conditions studied

  • Dupuytren's Disease

Browse trials for

03

In context

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

This study's planned enrollment of 172 is above the median of 72 across 57 interventional studies indexed under Dupuytren Contracture.

Browse Dupuytren Contracture studies →

Lead sponsor

Elsan is the lead sponsor of 68 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated
  • Indication of a surgery by aponeurectomy
  • Skin pinch of the posterior aspect of the arm of more than 1cm
  • Affiliation to a social security system
  • Patient informed of the study and having given

Exclusion criteria

Exclusion Criteria:

  • Previous surgery of any kind for Dupuytren's disease
  • Involvement on the thumb only
  • Need for a total skin graft or a pedicle flap on all the rays to be treated
  • Active disease
  • Previous treatment with collagenase
  • Pregnant and breastfeeding women
  • Patient under legal protection
  • to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Aponeurectomy with grafting

    The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.

    Procedure: Aponeurectomy with grafting

  • Active comparator
    Aponeurectomy alone

    The control group evaluates the aponeurectomy alone.

    Procedure: Aponeurectomy alone

Interventions

  • ProcedureAponeurectomy with grafting

    The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system. The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions.

  • ProcedureAponeurectomy alone

    The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.

06

What researchers measure

Primary outcomes

  1. 2-year recurrence rate of Dupuytren's disease

    Recurrence being defined as follows: appearance, at 2 years post-op compared to 6 weeks post-op, of a contracture of more than 20 degrees, with palpable cord, on any treated joint.

    Time frame: 2 Years after intervention

Secondary outcomes

  1. 3-year recurrence rate in both groups

    Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 3 years post-op compared to 6 weeks post-op

    Time frame: 3 Years after intervention

  2. 5-year recurrence rate in both groups

    Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 5 years post-op compared to 6 weeks post-op

    Time frame: 5 Years after intervention

  3. Comparison of the appearance of scars in both groups

    Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS). This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient). Each item is evaluated on 10 points. The lowest score is "1" which corresponds to the appearance of normal skin. A score of 10 indicates the greatest deviation from normal skin. The total score for each of the scales is obtained by adding the score for each of the 6 items. This total score can vary between 6 and 60 for each of the scales.

    Time frame: 1 Year after intervention

  4. Comparison of the appearance of scars in both groups

    Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS). This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient). Each item is evaluated on 10 points. The lowest score is "1" which corresponds to the appearance of normal skin. A score of 10 indicates the greatest deviation from normal skin. The total score for each of the scales is obtained by adding the score for each of the 6 items. This total score can vary between 6 and 60 for each of the scales.

    Time frame: 2 Years after intervention

  5. Comparison of the complication rates in both groups

    Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.

    Time frame: 1 Week after intervention

  6. Comparison of the complication rates in both groups

    Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.

    Time frame: 6 Weeks after intervention

  7. Comparison of the rate of occurrence of algodystrophy, regardless of cause

    Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.

    Time frame: 1 Year after intervention

  8. Comparison of the rate of occurrence of algodystrophy, regardless of cause

    Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.

    Time frame: 2 Years after intervention

  9. Comparison of the rate of occurrence of algodystrophy, regardless of cause

    Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.

    Time frame: 3 Years after intervention

  10. Comparison of the rate of occurrence of algodystrophy, regardless of cause

    Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.

    Time frame: 5 Years after intervention

  11. Comparison of the effect on quality of life in both groups

    Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.

    Time frame: 6 Weeks after intervention

  12. Comparison of the effect on quality of life in both groups

    Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.

    Time frame: 1 Year after intervention

  13. Comparison of the effect on quality of life in both groups

    Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.

    Time frame: 2 Years after intervention

  14. Comparison of the effect on quality of life in both groups

    Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.

    Time frame: 5 Years after intervention

  15. Evaluation of the primary endpoint on the second hand operated on.

    The surgery being done with or without fat according to the treatment of the 1st randomized hand (cross-over scheme). Data collection for the second surgery only if it occurs between the 1st hand surgery and the patient's protocol discharge.

    Time frame: Within five years after intervention

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Selles RW, Zhou C, Kan HJ, Wouters RM, van Nieuwenhoven CA, Hovius SER. Percutaneous Aponeurotomy and Lipofilling versus Limited Fasciectomy for Dupuytren's Contracture: 5-Year Results from a Randomized Clinical Trial. Plast Reconstr Surg. 2018 Dec;142(6):1523-1531. doi: 10.1097/PRS.0000000000004982. PubMed 30489526 ↗
  • Henry M. Dupuytren's disease: current state of the art. Hand (N Y). 2014 Mar;9(1):1-8. doi: 10.1007/s11552-013-9563-0. PubMed 24570630 ↗
  • Engstrand C, Krevers B, Nylander G, Kvist J. Hand function and quality of life before and after fasciectomy for Dupuytren contracture. J Hand Surg Am. 2014 Jul;39(7):1333-1343.e2. doi: 10.1016/j.jhsa.2014.04.029. PubMed 24969497 ↗
  • Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):108S-120S. doi: 10.1097/01.prs.0000234610.81672.e7. PubMed 16936550 ↗
  • Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001 Apr;7(2):211-28. doi: 10.1089/107632701300062859. PubMed 11304456 ↗
  • Mojallal A, Lequeux C, Shipkov C, Breton P, Foyatier JL, Braye F, Damour O. Improvement of skin quality after fat grafting: clinical observation and an animal study. Plast Reconstr Surg. 2009 Sep;124(3):765-774. doi: 10.1097/PRS.0b013e3181b17b8f. PubMed 19730294 ↗
  • Verhoekx JSN, Mudera V, Walbeehm ET, Hovius SER. Adipose-derived stem cells inhibit the contractile myofibroblast in Dupuytren's disease. Plast Reconstr Surg. 2013 Nov;132(5):1139-1148. doi: 10.1097/PRS.0b013e3182a3bf2b. PubMed 23924646 ↗
  • Foucher G, Medina J, Navarro R. Percutaneous needle aponeurotomy: complications and results. J Hand Surg Br. 2003 Oct;28(5):427-31. doi: 10.1016/s0266-7681(03)00013-5. PubMed 12954251 ↗
  • Kan HJ, Verrijp FW, Hovius SER, van Nieuwenhoven CA; Dupuytren Delphi Group; Selles RW. Recurrence of Dupuytren's contracture: A consensus-based definition. PLoS One. 2017 May 15;12(5):e0164849. doi: 10.1371/journal.pone.0164849. eCollection 2017. PubMed 28505187 ↗
  • Beaton DE, Wright JG, Katz JN; Upper Extremity Collaborative Group. Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am. 2005 May;87(5):1038-46. doi: 10.2106/JBJS.D.02060. PubMed 15866967 ↗
  • Mintken PE, Glynn P, Cleland JA. Psychometric properties of the shortened disabilities of the Arm, Shoulder, and Hand Questionnaire (QuickDASH) and Numeric Pain Rating Scale in patients with shoulder pain. J Shoulder Elbow Surg. 2009 Nov-Dec;18(6):920-6. doi: 10.1016/j.jse.2008.12.015. Epub 2009 Mar 17. PubMed 19297202 ↗
  • Sawaya ET, Sommier B, Alet JM, Piechaud PT; REMEDY Study Group; ReSurg; Lecoq FA. Limited fasciectomy with versus without autologous adipose tissue grafting for treatment of Dupuytren's contracture (REMEDY): study protocol for a multicentre randomised controlled trial. Trials. 2024 Sep 2;25(1):577. doi: 10.1186/s13063-024-08410-4. PubMed 39223657 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Mar 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Oct 5, 2021
StartActual
Sep 29, 2022
Primary completionEst.
Mar 29, 2027
CompletionEst.
Mar 29, 2030
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05067764
Lead sponsor
Elsan
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Sep 29, 2022
Primary completion
Mar 29, 2027 (estimated)
Completion
Mar 29, 2030 (estimated)
Last update
Apr 23, 2026

Study contacts

Elias SAWAYA, MD
Contact
esawaya.md@gmail.com
(0)663420278 ext. +33
Elias SAWAYA, MD
principal investigator · Institut Aquitain de la Main

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion